Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06535919 · ClinicalTrials.gov registry record

Substance Use Treatment and Its Role in Supporting Social Cognition

A clinical trial of Substance Use and Empathy, sponsored by Nova Southeastern University.

Recruiting
Registry status
108
Enrollment target
2
Study locations

NCT06535919: Recruiting study of Substance Use and Empathy, sponsored by Nova Southeastern University.

NCT06535919 is a study of Substance Use and Empathy that is actively recruiting participants, run by Nova Southeastern University. The registered enrollment target is 108 participants, below the 1,259-participant average among 88 other Substance Use trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06535919, a study of Substance Use and Empathy, is actively recruiting participants, sponsored by Nova Southeastern University.

RECRUITING
Registry status
108 participants
Enrollment target
2
Study locations

Study Summary

This study aims to assess changes in empathy levels before and after residential treatment among individuals with substance use disorders.

Primary Outcome

The Empathy Quotient-Short (EQ-Short) is a self-report questionnaire designed to assess individual differences in empathy. It is used to measure levels of empathy, including affective, cognitive, and total empathy. The unit of measure for the outcome is the total empathy score derived from responses to 22 items, with each item rated on a 4-point Likert scale ranging from 1 ("I strongly disagree") to 4 ("I strongly agree"). Possible range 0-44, Higher scores indicate greater empathy. For example,

Conditions Studied

Interventions

  • BEHAVIORAL Treatment as Usual

Study Locations (2)

Florida

  • Recovery Unplugged - Fort Lauderdale
  • Recovery Unplugged - Lake Worth

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2024-10-22
Est. Completion 2026-01
Nova Southeastern University

71 total trials

What NCT06535919 shows while recruiting

NCT06535919 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,259-participant average among 88 other Substance Use trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Substance Use appearing as the primary indexed condition, and to 1 intervention - of which Treatment as Usual is the first listed.

NCT06535919 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06535919 about?

NCT06535919 is a clinical study titled "Substance Use Treatment and Its Role in Supporting Social Cognition". This study aims to assess changes in empathy levels before and after residential treatment among individuals with substance use disorders.

What is the current status of trial NCT06535919?

This trial is currently recruiting. The enrollment target is 108 participants. The study started on 2024-10-22. Estimated completion is 2026-01.

What conditions does trial NCT06535919 study?

This clinical trial studies the following conditions: Substance Use, Empathy.

What interventions are being tested in trial NCT06535919?

The interventions under investigation include: Treatment as Usual (BEHAVIORAL).

Who is sponsoring clinical trial NCT06535919?

This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06535919 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06535919's enrollment target sits among peer trials

108 62nd of 88 higher than 27 of 88 other Substance Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02703207 · 108 participants · NA

    Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

  • NCT02744677 · 108 participants · NA

    COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

  • NCT02781883 · 108 participants · Phase 2

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • NCT03848663 · 108 participants · NA

    Visual Remapping to Aid Reading With Field Loss

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06535919, the US trial registry maintained by the National Library of Medicine. NCT06535919 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.